HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.170

-0.230-2.21%

Volume:2.48M

Turnover:25.19M

Market Cap:4.14B

PE:-11.47

High:10.370

Open:10.350

Low:10.080

Close:10.400

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.63

T/O Rate:0.79%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.887

ROE:-36.78%

ROA:-20.32%

PB:4.04

PE(LYR):-11.47

PS:100.08

Loading ...

Overview Company News Filings

Transthera Sciences (Nanjing) Inc - Gross Proceeds Expected at HK$156.62 Mln, Net Proceeds at HK$152.13 Mln

THOMSON REUTERS

TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial

MT Newswires Live

TRANSTHERA-B's Core Product Demonstrates Efficacy in Advanced Solid Tumors in Nature Communications Publication

TransThera Highlights Promising Phase Ib/II Results for Tinengotinib in Nature Communications

Bulletin Express

Stock Track | TRANSTHERA-B Plummets 5.70% Intraday on Clinical Data Release and Sector Weakness

TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million

Bulletin Express

TRANSTHERA-B's Third Fundraising in Under a Year: 18% Discounted Placement Raises HK$290 Million While Prior Funds Remain Unused

TransThera聚焦创新药研发，2025年净亏损约2.96亿元，核心管线获监管突破

Bulletin Express

TransThera unveils inaugural ESG report: Tinengotinib NDA accepted, 2025 greenhouse-gas emissions at 728.89 t

Bulletin Express

Transthera Sciences publishes 2025 annual report

TransThera Completes HK$290.00 Million H-Share Placement at HK$57.03 Each, Expanding Free Float by 1.65%

Bulletin Express

TRANSTHERA-B Completes Placement of 5.085 Million Shares, Raising Approximately HK$282 Million Net

Transthera files HKEX return on 5,085,000 H-share issue at HKD 57.03

TransThera Sciences completes HK$290 million H-share placement at HK$57.03 each

TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR

TransThera Highlights FGFR-JAK–Mediated Resistance in HR+ Breast Cancer and Showcases Tinengotinib Preclinical Efficacy at AACR 2026

Bulletin Express

TransThera Sciences presents tinengotinib preclinical data at AACR annual meeting

TransThera Sciences Doses First Patient in Cholangiocarcinoma Drug Trial

MT Newswires Live

TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma

TransThera doses first patient in China Phase III tinengotinib trial for advanced cholangiocarcinoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02617/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.17,"timestamp":1788163726522,"preClose":10.4,"halted":0,"volume":2479500,"delay":0,"changeRate":-0.022115384615384655,"floatShares":312000000,"shares":407000000,"eps":-0.886553496974827,"marketStatus":"Not Yet Opened","change":-0.23,"latestTime":"08-31 16:08:46","open":10.35,"high":10.37,"low":10.08,"amount":25194615,"amplitude":0.027885,"askPrice":10.17,"askSize":48500,"bidPrice":10.16,"bidSize":29500,"shortable":3,"etf":0,"ttmEps":-0.7845695153609832,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.4,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.6301784171215122,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.886553,"volumeRatio":0.6301784171215122,"shares":407000000,"dividePrice":0,"high":10.37,"amplitude":0.027885,"preClose":10.4,"low":10.08,"week52Low":9.01,"pbRate":"4.04","psRate":"100.08","week52High":679.5,"institutionHeld":0,"latestPrice":10.17,"committee":-0.24359,"eps":-0.886553496974827,"divideRate":0,"volume":2479500,"delay":0,"ttmEps":-0.7845695153609832,"open":10.35,"prevYearClose":114.9,"prevWeekClose":10.4,"prevMonthClose":10.17,"prevQuarterClose":11.55,"fiveDayClose":9.975,"twentyDayClose":10,"sixtyDayClose":33.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-08-28","current":-12.962523,"percent":0.869863,"low":-380.446233,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"high":-10.87103,"avg":-113.01539,"sd":96.275788,"marketCap":4242353783},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783}],"updateTime":1788213833200},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636004091","title":"Transthera Sciences (Nanjing) Inc - Gross Proceeds Expected at HK$156.62 Mln, Net Proceeds at HK$152.13 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2636004091","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636004091?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:30","pubTimestamp":1779143448,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V1H7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636049845","title":"TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636049845","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636049845?lang=en_us&edition=fundamental","pubTime":"2026-05-18 12:12","pubTimestamp":1779077575,"startTime":"0","endTime":"0","summary":"TransThera Sciences   said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153908883","title":"TRANSTHERA-B's Core Product Demonstrates Efficacy in Advanced Solid Tumors in Nature Communications Publication","url":"https://stock-news.laohu8.com/highlight/detail?id=1153908883","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153908883?lang=en_us&edition=fundamental","pubTime":"2026-05-17 18:48","pubTimestamp":1779014915,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced the publication of exploratory clinical results for its core product, tienegotinib, both as a monotherapy and in combination with atezolizumab for treating advanced...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183414332","title":"TransThera Highlights Promising Phase Ib/II Results for Tinengotinib in Nature Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1183414332","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183414332?lang=en_us&edition=fundamental","pubTime":"2026-05-17 18:42","pubTimestamp":1779014561,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) reported new Phase Ib/II data showing that its spectrum-selective multi-kinase inhibitor tinengotinib delivered notable antitumor activity both as a standalone therapy...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151965178","title":"Stock Track | TRANSTHERA-B Plummets 5.70% Intraday on Clinical Data Release and Sector Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1151965178","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151965178?lang=en_us&edition=fundamental","pubTime":"2026-05-13 11:41","pubTimestamp":1778643704,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B's stock fell sharply by 5.70% during intraday trading on Wednesday.The decline followed the release of clinical data for the company's core product tiengoitinib, presented at the 2026...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141413135","title":"TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1141413135","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141413135?lang=en_us&edition=fundamental","pubTime":"2026-05-06 16:03","pubTimestamp":1778054607,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. filed its Monthly Return for the period ended 30 April 2026, highlighting a placement-driven expansion of its equity base. The company allotted 5.09 million new H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162258215","title":"TRANSTHERA-B's Third Fundraising in Under a Year: 18% Discounted Placement Raises HK$290 Million While Prior Funds Remain Unused","url":"https://stock-news.laohu8.com/highlight/detail?id=1162258215","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162258215?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:12","pubTimestamp":1777543925,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617.HK), a Hong Kong-listed pre-revenue biotech company, announced a new share placement after market close on April 14, 2026. The company plans to issue 5.085 million new H shares at...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190223337","title":"TransThera聚焦创新药研发，2025年净亏损约2.96亿元，核心管线获监管突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1190223337","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190223337?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:49","pubTimestamp":1776955792,"startTime":"0","endTime":"0","summary":"根据TransThera Sciences (Nanjing), Inc.（以下简称“公司”）披露的2025年度报告，报告期内公司继续专注于肿瘤及炎症等领域的小分子药物研发，尚未实现收入，全年净亏损由上一年度的人民币2.7461亿元扩大至人民币2.9596亿元（同比增长约7.8%）。公司董事会及管理层在年内继续强化内部治理结构，研发投入占主要成本比例，核心产品在临床与注册方面取得重要突破。...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TransThera聚焦创新药研发，2025年净亏损约2.96亿元，核心管线获监管突破","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113824509","title":"TransThera unveils inaugural ESG report: Tinengotinib NDA accepted, 2025 greenhouse-gas emissions at 728.89 t","url":"https://stock-news.laohu8.com/highlight/detail?id=1113824509","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113824509?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:47","pubTimestamp":1776955626,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. released its first Environmental, Social and Governance Report, covering operations from 1 January to 31 December 2025 and focusing on headquarters, R&D centre and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629725858","title":"Transthera Sciences publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629725858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629725858?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:33","pubTimestamp":1776954802,"startTime":"0","endTime":"0","summary":"Global expansion remained central, supported by a registrational Phase III multi-regional trial for Tinengotinib across U.S., EU, U.K., South Korea, Taiwan; enrollment expected to complete in 2026.Pipeline breadth increased, with six clinical-stage candidates spanning oncology, inflammatory, cardiometabolic diseases; Tinengotinib programs advanced in prostate cancer, breast cancer, liver cancer.Business development accelerated via November 2025 NLRP3 collaboration with Neurocrine Biosciences, carrying potential total value up to USD 881.5 million.Management outlook targeted China NDA approval in 2026 for Tinengotinib, with commercialization team buildout planned for 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Scienc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL1LmypC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245756.USD","LU2065171402.SGD","LU0320765992.SGD","LU0154245673.USD","BK4139","02617","LU0823416689.USD","LU2065171311.SGD","NBIX","LU2324357040.USD","LU0109394709.USD","LU2065170008.USD","LU0889565916.HKD","BK1161","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106715629","title":"TransThera Completes HK$290.00 Million H-Share Placement at HK$57.03 Each, Expanding Free Float by 1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106715629","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106715629?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:23","pubTimestamp":1776770596,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. announced the successful completion of its new H-share placement on 21 April 2026. A total of 5.09 million H shares were placed with no fewer than six professional...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112729517","title":"TRANSTHERA-B Completes Placement of 5.085 Million Shares, Raising Approximately HK$282 Million Net","url":"https://stock-news.laohu8.com/highlight/detail?id=1112729517","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112729517?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:08","pubTimestamp":1776769703,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced the fulfillment of all conditions under the placement agreement, with the placement completed on April 21, 2026. The placing agent successfully allocated a total of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033567","title":"Transthera files HKEX return on 5,085,000 H-share issue at HKD 57.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033567","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629033567?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:06","pubTimestamp":1776769609,"startTime":"0","endTime":"0","summary":"TransThera Sciences filed a next day disclosure return reporting issuance of 5,085,000 new H shares on April 21, 2026.Issued shares outstanding rose to 308,851,673 from 303,766,673.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLdzmHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629333070","title":"TransThera Sciences completes HK$290 million H-share placement at HK$57.03 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2629333070","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629333070?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769486,"startTime":"0","endTime":"0","summary":"TransThera Sciences completed private placement of 5,085,000 new H shares at HK$ 57.03 each on April 21, 2026.Gross proceeds totaled about HK$ 290 million; net proceeds were about HK$ 282.2 million.Funds earmarked mainly for R&D and clinical development of Tinengotinib, with additional allocation toward manufacturing and commercialization in China.Total issued shares rose to 404,082,633 from 398,997,633 following issue of placing shares.Placees bought about 1.3% of enlarged share capital; none became substantial shareholder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Excha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL48jwCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121493501","title":"TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1121493501","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121493501?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:10","pubTimestamp":1776730218,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the company presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The poster disclosed lineage plasticity as a driver...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4225","HR","BK4203","BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184291572","title":"TransThera Highlights FGFR-JAK–Mediated Resistance in HR+ Breast Cancer and Showcases Tinengotinib Preclinical Efficacy at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1184291572","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184291572?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:02","pubTimestamp":1776729777,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera) released new translational and preclinical findings at the 2026 American Association for Cancer Research (AACR) Annual Meeting, identifying lineage...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629041772","title":"TransThera Sciences presents tinengotinib preclinical data at AACR annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629041772","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629041772?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:00","pubTimestamp":1776729643,"startTime":"0","endTime":"0","summary":"TransThera Sciences will present a poster at AACR Annual Meeting on April 20, 2026, 9:00 AM–12:00 PM PDT.Presentation will cover endocrine therapy resistance in HR+ breast cancer, citing convergent FGFR-JAK signaling as a driver of lineage reprogramming.Poster will also show preclinical data indicating tinengotinib restored luminal identity, resensitizing resistant models to endocrine therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3vdWMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628278208","title":"TransThera Sciences Doses First Patient in Cholangiocarcinoma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628278208","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628278208?lang=en_us&edition=fundamental","pubTime":"2026-04-17 19:10","pubTimestamp":1776424232,"startTime":"0","endTime":"0","summary":"TransThera Sciences   dosed the first patient in a confirmatory phase III clinical trial of Tinengotinib, according to a Friday Hong Kong bourse filing.The drug is being tested as a monotherapy for the treatment of patients with advanced cholangiocarcinoma, the clinical-stage biopharmaceutical firm said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176775881","title":"TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1176775881","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176775881?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:44","pubTimestamp":1776422683,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","III","BK4134","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628270114","title":"TransThera doses first patient in China Phase III tinengotinib trial for advanced cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2628270114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628270114?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:40","pubTimestamp":1776422454,"startTime":"0","endTime":"0","summary":"TransThera dosed first patient in China confirmatory Phase III trial of tinengotinib monotherapy for advanced intrahepatic cholangiocarcinoma with FGFR2 alterations.Study will compare tinengotinib versus chemotherapy in patients whose disease relapsed or progressed following first-line systemic therapy.No clinical results were presented; efficacy and safety readout will be generated in future as trial progresses.Program supports marketing push in China, with tinengotinib already at NDA review stage following completion of pivotal Phase II study.Company positioned drug as potential option for patients previously treated with FGFR inhibitors, targeting unmet need tied to treatment resistance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL57VbVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":148,"code":"91000000","status":"200"}]}}